Bristol-Myers Squibb Company
345 Park Avenue
About Bristol-Myers Squibb Company
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
Founder: Edward Robinson Squibb
CEO: Giovanni Caforio, MD
CFO: Charles Bancroft
Please click here for clinical trial information.
Please click here for Bristol-Myers Squibb job opportunities.
Please click here to see all products.
For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.
FOLLOW BRISTOL-MYERS SQUIBB:
Tweets by Bristol-Myers Squibb
1763 articles with Bristol-Myers Squibb Company
The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Imfinzi to treat patients with unresectable Stage III non-small cell lung cancer (NSCLC).
This week MA-based real estate firm Calare Properties acquired the land and buildings for $5M.
Rumors of Nektar Therapeutics being up for sale may have been premature.
Bristol-Myers Squibb Demonstrates Their Commitment to Site Relationships by Joining SCRS' Global Impact Partner Program
SCRS announced today that BMS has joined the organization as a Global Impact Partner.
Sirenas will receive an undisclosed upfront payment, funding for research activities and potential success fees from Bristol-Myers Squibb.
BMS shares climb more than 4% this morning after the company announced its anticipated Phase III CheckMate-227 study data.
Bristol-Myers Squibb posted fourth quarter 2017 revenues of $5.4 billion, an increase of 4% compared to the same period a year ago.
Five Prime Therapeutics Announces $25M Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone
Initiation of Phase 2 study of Cabiralizumab plus Opdivo in advanced pancreatic cancer.
1/23/2018The year is already off to a good start with mergers and acquisitions in the biopharma industry.
European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
The EC approval marks Bristol-Myers Squibb’s first pediatric indication for an Immuno-Oncology medicine in the European Union (EU) and allows for the marketing of Yervoy for this indication in all 28 Member States of the EU.
Bristol-Myers Squibb Company Release: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer
With a median of 13.4 months of follow-up, the primary endpoint of objective response rate (ORR) per investigator assessment was 55% (95% CI: 45.2 to 63.8).
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference.
These prominent drug developers look to be enticing buys this month.
The expense is primarily related to taxes on unremitted offshore earnings, the company said.
PGDx is a leader in the development of tissue-based and liquid biopsy technologies and products for cancer genomics.
Immuno-oncology therapeutics have revolutionized certain types of cancer treatments, and they are, in many ways, as close to miracle cures as we’ve seen in decades.
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients With Completely Resected Melanoma With Lymph Node Involvement or Metastatic Disease
Bristol-Myers Squibb announced today that the FDA has approved Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
In conjunction with this collaboration, Bristol-Myers Squibb also made an equity investment in TARIS.
During a conference call at 8:00 a.m. ET on February 5th company executives will review financial information and will address inquiries from investors and analysts.
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoy (ipilimumab) for the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Bristol-Myers Squibb announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Yervoy (ipilimumab) for pediatric patients 12 years of age and older who have unresectable or metastatic melanoma.